NASDAQ$DH
Definitive Healthcare Corp · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Revenue increased, driven by enterprise client base growth and strategic product releases.
Definitive Healthcare reported strong second-quarter results with a 37% year-over-year revenue increase to $54.5 million. The company also demonstrated the leverage of its business model with adjusted EBITDA.
- Revenue was $54.5 million, an increase of 37% from Q2 2021.
- Net loss was ($9.6) million, compared to ($15.0) million in Q2 2021.
- Adjusted EBITDA was $16.3 million, or 30% of revenue, compared to $14.4 million, or 36% of revenue in Q2 2021.
- Unlevered free cash flow was $19.1 million, or 35% of revenue.
Headline financials
Revenue & EPS history
Definitive Healthcare · Revenue · Quarterly
$54.5M
Forward guidance
The Company is issuing the following financial guidance based on information as of August 4, 2022.
Tailwinds
- Third Quarter 2022 Revenue is expected to be in the range of $56.0 – $57.0 million, a 31% increase year over year.
- Third Quarter 2022 Adjusted Operating Income is expected to be in the range of $14.5– $15.5 million.
- Third Quarter 2022 Adjusted EBITDA is expected to be in the range of $15.5– $16.5 million.
- Third Quarter 2022 Adjusted Net Income is expected to be $6.5 – $7.5 million.
- Third Quarter 2022 Adjusted Net Income Per Diluted Share is expected to be $0.03 – $0.05 on approximately 155.4 million weighted-average shares outstanding.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2022
-3.2%
Avg return
Earnings day
-5.7%
Avg return
5 days after
-5.8%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+31.7%
Q1 2025
Best reaction
-34.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.0% | -5.2% | |
| Q4 2025 | -8.6% | -12.9% | -25.0% | |
| Q3 2025 | +11.9% | +2.6% | -6.4% | |
| Q1 2025 | +31.7% | +21.4% | +33.1% | |
| Q4 2024 | -34.3% | -43.7% | -40.2% | |
| Q3 2024 | -1.4% | +6.3% | +8.4% | |
| Q2 2024 | -1.4% | +5.1% | +21.6% | |
| Q1 2024 | -27.1% | -27.5% | -22.9% | |
| Q4 2023 | +2.3% | -4.2% | -13.3% | |
| Q3 2023 | +27.5% | +29.5% | +49.5% | |
| Q2 2023 | -4.0% | -6.2% | -21.2% | |
| Q1 2023 | +0.9% | -3.7% | +7.9% | |
| Q4 2022 | +3.5% | -1.6% | -11.5% | |
| Q3 2022 | -25.0% | -29.7% | -14.5% | |
| Q2 2022 | -16.3% | -18.6% | -35.7% | |
| Q1 2022 | -17.5% | -31.3% | -19.4% | |
| Q4 2021 | +7.6% | +13.6% | +14.0% | |
| Q3 2021 | -5.8% | +0.2% | -23.3% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro